Eli Lilly and Co. stock presents cancer data, little changed pre-market
Published on 10/26/2026 at 08:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data ahead
- Eli Lilly presented first clinical data in platinum-sensitive ovarian cancer on October 24, 2026.
- The company’s Q3 2026 earnings call is scheduled for October 29, 2026.
- Eli Lilly and Co. stock trades pre-market at EUR 1,141.40 at 8:31 a.m. CET at Lang & Schwarz on October 26, 2026, 0.28 percent below the Xetra close of October 23, 2026.
Eli Lilly and Company presented first clinical data in platinum-sensitive ovarian cancer for an investigational next-generation FR?-targeting antibody-drug conjugate at ESMO 2026 on October 24, 2026, according to the company’s investor relations site. Eli Lilly and Co. stock trades pre-market at EUR 1,141.40 at 8:31 a.m. CET at Lang & Schwarz on October 26, 2026, 0.28 percent below the Xetra close of October 23, 2026 (EUR 1,144.60).
Lilly presents ovarian cancer data
The company described the treatment as investigational and next-generation, with the data presented at the European Society for Medical Oncology congress. The investor relations site also lists Lilly’s Q3 2026 earnings call for October 29, 2026 at 10:00 a.m. EDT.
Ahead of the Xetra open
The Lang & Schwarz indication is EUR 3.20 below the reference level. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
The group and its market
Eli Lilly and Company develops and sells medicines across therapeutic areas including endocrinology, oncology, immunology and neurology, according to MarketScreener. The next company event listed by Lilly is the October 29, 2026 earnings call. Market context: Market report S&P 500.
